Could Dyne Therapeutics' (DYN) AMCP Spotlight Reveal How New FDA Leadership May Shape Its Pipeline? [Yahoo! Finance]
Dyne Therapeutics, Inc. (DYN)
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm
Check Earnings Report
US:NYSE Investor Relations:
dynegy.com/investors/presentations-events
Company Research
Source: Yahoo! Finance
At the same time, the prospect of Dr. Houman Hemmati leading the FDA's Center for Biologics Evaluation and Research introduces a potential shift in the regulatory framework governing Dyne's biologics and gene therapy programs. We'll now examine how the potential CBER leadership change may influence Dyne Therapeutics' investment narrative and long-term regulatory outlook. The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. What Is Dyne Therapeutics' Investment Narrative? For Dyne Therapeutics, the big picture an investor needs to believe in is that its FORCE platform can translate encouraging DMD and DM1 data into approved products before the balance sheet strain becomes overwhelming. The key near term catalysts still sit firmly in the clinic: progression of the Phase 3 HARMONIA trial in DM1, regulatory clarity around potential accelerated paths for DYNE-251, and additional fun
Show less
Read more
Impact Snapshot
Event Time:
DYN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYN alerts
High impacting Dyne Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DYN
News
- Dyne Therapeutics (DYN) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines [TheStreet.com]TheStreet.com
- Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular MedicinesGlobeNewswire
- Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs [Yahoo! Finance]Yahoo! Finance
DYN
Earnings
- 3/2/26 - Miss
DYN
Sec Filings
- 4/21/26 - Form 144
- 4/21/26 - Form 144
- 4/21/26 - Form 144
- DYN's page on the SEC website